Literature DB >> 21538443

Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis.

Aijuan Qu1, Matthew Taylor, Xiang Xue, Tsutomu Matsubara, Daniel Metzger, Pierre Chambon, Frank J Gonzalez, Yatrik M Shah.   

Abstract

UNLABELLED: Oxygen dynamics in the liver is a central signaling mediator controlling hepatic homeostasis, and dysregulation of cellular oxygen is associated with liver injury. Moreover, the transcription factor relaying changes in cellular oxygen levels, hypoxia-inducible factor (HIF), is critical in liver metabolism, and sustained increase in HIF signaling can lead to spontaneous steatosis, inflammation, and liver tumorigenesis. However, the direct responses and genetic networks regulated by HIFs in the liver are unclear. To help define the HIF signal-transduction pathway, an animal model of HIF overexpression was generated and characterized. In this model, overexpression was achieved by Von Hippel-Lindau (Vhl) disruption in a liver-specific temporal fashion. Acute disruption of Vhl induced hepatic lipid accumulation in an HIF-2α-dependent manner. In addition, HIF-2α activation rapidly increased liver inflammation and fibrosis, demonstrating that steatosis and inflammation are primary responses of the liver to hypoxia. To identify downstream effectors, a global microarray expression analysis was performed using livers lacking Vhl for 24 hours and 2 weeks, revealing a time-dependent effect of HIF on gene expression. Increase in genes involved in fatty acid synthesis were followed by an increase in fatty acid uptake-associated genes, and an inhibition of fatty acid β-oxidation. A rapid increase in proinflammatory cytokines and fibrogenic gene expression was also observed. In vivo chromatin immunoprecipitation assays revealed novel direct targets of HIF signaling that may contribute to hypoxia-mediated steatosis and inflammation.
CONCLUSION: These data suggest that HIF-2α is a critical mediator in the progression from clinically manageable steatosis to more severe steatohepatitis and liver cancer, and may be a potential therapeutic target.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21538443      PMCID: PMC3145012          DOI: 10.1002/hep.24400

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  40 in total

1.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

2.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

3.  Angptl3 regulates lipid metabolism in mice.

Authors:  Ryuta Koishi; Yosuke Ando; Mitsuru Ono; Mitsuru Shimamura; Hiroaki Yasumo; Toshihiko Fujiwara; Hiroyoshi Horikoshi; Hidehiko Furukawa
Journal:  Nat Genet       Date:  2002-01-14       Impact factor: 38.330

4.  Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.

Authors:  V H Haase; J N Glickman; M Socolovsky; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

5.  Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic Kupffer cells.

Authors:  Bryan L Copple; Shan Bai; Jeon-Ok Moon
Journal:  Hepatol Res       Date:  2010-04-14       Impact factor: 4.288

6.  Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans.

Authors:  Stefano Romeo; Wu Yin; Julia Kozlitina; Len A Pennacchio; Eric Boerwinkle; Helen H Hobbs; Jonathan C Cohen
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

Review 7.  Lysyl oxidase: mechanism, regulation and relationship to liver fibrosis.

Authors:  H M Kagan
Journal:  Pathol Res Pract       Date:  1994-10       Impact factor: 3.250

8.  The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms.

Authors:  Lu Shan; Xuan-Chuan Yu; Ziye Liu; Yi Hu; Lydia T Sturgis; Maricar L Miranda; Qingyun Liu
Journal:  J Biol Chem       Date:  2008-11-21       Impact factor: 5.157

9.  Hypoxia-inducible factor-dependent production of profibrotic mediators by hypoxic hepatocytes.

Authors:  Bryan L Copple; Juan J Bustamante; Timothy P Welch; Nam Deuk Kim; Jeon-Ok Moon
Journal:  Liver Int       Date:  2009-03-19       Impact factor: 5.828

10.  Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death.

Authors:  B Kucejova; N E Sunny; A D Nguyen; R Hallac; X Fu; S Peña-Llopis; R P Mason; R J Deberardinis; X-J Xie; R Debose-Boyd; V D Kodibagkar; S C Burgess; J Brugarolas
Journal:  Oncogene       Date:  2011-01-10       Impact factor: 9.867

View more
  78 in total

Review 1.  Angiogenesis and liver fibrosis.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Pathophysiology of lipid droplet proteins in liver diseases.

Authors:  Rotonya M Carr; Rexford S Ahima
Journal:  Exp Cell Res       Date:  2015-10-26       Impact factor: 3.905

Review 3.  Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road.

Authors:  Jing-Si Wang; Qiu-Yun Zhang; Jin-Lian Cheng; Lan-Yu Chen; Nai-Li Yao; Gui-Zhi Sun; Yu-Ling Chu
Journal:  Chin J Integr Med       Date:  2018-06-25       Impact factor: 1.978

4.  Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice.

Authors:  Jessica A Bonzo; Christina H Ferry; Tsutomu Matsubara; Jung-Hwan Kim; Frank J Gonzalez
Journal:  J Biol Chem       Date:  2012-01-12       Impact factor: 5.157

5.  Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis.

Authors:  Cen Xie; Tomoki Yagai; Yuhong Luo; Xianyi Liang; Tao Chen; Qiong Wang; Dongxue Sun; Jie Zhao; Sadeesh K Ramakrishnan; Lulu Sun; Chunmei Jiang; Xiang Xue; Yuan Tian; Kristopher W Krausz; Andrew D Patterson; Yatrik M Shah; Yue Wu; Changtao Jiang; Frank J Gonzalez
Journal:  Nat Med       Date:  2017-10-09       Impact factor: 53.440

Review 6.  Ischaemia reperfusion injury in liver transplantation: Cellular and molecular mechanisms.

Authors:  Wasim A Dar; Elise Sullivan; John S Bynon; Holger Eltzschig; Cynthia Ju
Journal:  Liver Int       Date:  2019-04-02       Impact factor: 5.828

7.  Obstructive sleep apnea and hypoxemia are associated with advanced liver histology in pediatric nonalcoholic fatty liver disease.

Authors:  Shikha S Sundaram; Ronald J Sokol; Kelley E Capocelli; Zhaoxing Pan; Jillian S Sullivan; Kristen Robbins; Ann C Halbower
Journal:  J Pediatr       Date:  2013-12-07       Impact factor: 4.406

Review 8.  The role of hypoxia-inducible factors in metabolic diseases.

Authors:  Frank J Gonzalez; Cen Xie; Changtao Jiang
Journal:  Nat Rev Endocrinol       Date:  2018-12       Impact factor: 43.330

9.  Role of Myc in hepatocellular proliferation and hepatocarcinogenesis.

Authors:  Aijuan Qu; Changtao Jiang; Yan Cai; Jung-Hwan Kim; Naoki Tanaka; Jerrold M Ward; Yatrik M Shah; Frank J Gonzalez
Journal:  J Hepatol       Date:  2013-10-02       Impact factor: 25.083

Review 10.  Hypoxia-inducible factors and innate immunity in liver cancer.

Authors:  Vincent Wai-Hin Yuen; Carmen Chak-Lui Wong
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.